Navigation Links
Frost & Sullivan: Expiration of Patents for Leading Drugs to Bolster the Oral Solid Drug Dosage Excipients Market in North America
Date:6/25/2013

MOUNTAIN VIEW, Calif., June 25, 2013 /PRNewswire/ -- Best-selling drugs with a combined worth of $73.85 billion that include Lipitor, Actos and Plavix are expected to lose patent protection in the United States by 2017. As a result, an influx of generic manufacturers and an increased volume of new drugs is expected in the market, thus sustaining the demand for oral solid drug dosage excipients in North America. These inert substances serve as vehicles for active ingredients in drugs and include binders and fillers, disintegrants, coatings, flavors, colors, sweeteners, glidants, adhesives and lubricants.

New analysis from Frost & Sullivan (http://www.chemicals.frost.com), Analysis of the North American Oral Solid Drug Dosage Excipients Market, finds that the market earned revenue of $1.19 billion in 2012 and estimates this to reach $1.70 billion in 2019 at a compound annual growth rate of 5.4 percent.

If you are interested in more information on this research, please send an e-mail to Jeannette Garcia, Corporate Communications, at jeannette.garcia@frost.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.

"The need to improve drug manufacturing processes and the quality of drug formulations has led to the production of multi-functional excipients with better manufacturing accuracy and purity," said Frost & Sullivan Chemicals, Materials and Food Industry Analyst Dr. Nandhini Rajagopal, Ph.D. "The upcoming cost-effective tablet processing method, in particular, will require excipients with excellent functionalities and improved physical and chemical properties."

Cost containment efforts by the governm
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
2. Frost & Sullivan: mHealth Serves as the Catalyst for Healthcares Evolution
3. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
4. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
5. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
8. Frost & Sullivan Market Share Leadership Award Highlights Acuo Technologies Accomplishments in Enterprise Imaging Informatics
9. Mega Trends Foster Investment, Innovation and Expansion in Latin America, Finds Frost & Sullivan
10. Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
11. Frost & Sullivan: Opportunities for Electronics Manufacturing Services in Medical Industry Increasing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... MALVERN, Pa. , April 27, 2015 /PRNewswire/ ... development and commercialization of products focused on the ... executive team of William Stewart and ... mark important steps in SCILEX,s proprietary drug development ... of its products. The Company,s first product, ZTlido™ ...
(Date:4/27/2015)... 27, 2015 Harwood Feffer LLP ( www.hfesq.com ... directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") ... breached its fiduciary duties to shareholders. On ... announcing results from its first Phase 3 registration trial ... that in the trial, Rhopressa failed to meet its ...
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
Breaking Medicine Technology:SCILEX Pharmaceuticals Announces Commercial Executive Appointments 2SCILEX Pharmaceuticals Announces Commercial Executive Appointments 3Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2
... March 06, 2007 /PRNewswire/ -- Up to two ... up to 600,000,hospitalized. Its primary complication, pulmonary embolism ... than breast cancer and,AIDS combined. People who suffer ... DVT, because these factors also heighten the,likelihood of ...
... POZEN Inc.,(NASDAQ: POZN), today announced top-line results of its ... of 2006. PA 325 is a patented formulation of ... immediate release,formulation of a proton pump inhibitor., The PA ... subjects,over the age of 50. Each subject was treated ...
Cached Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 2POZEN Announces Positive Outcome for PA 325 Proof of Concept Study 3
(Date:4/27/2015)... The Doctors on Liens mission for over ... attorneys with the best doctors working on a lien basis. ... their history and that trend continues with the addition of ... in the Tujunga / Sunland area. Featuring ... can find comprehensive care and detailed documentation of their injuries. ...
(Date:4/27/2015)... Sitting or standing for long periods of time can ... those whose occupation requires them to be sitting while they ... to be on their feet for most of the day, ... severe and longer lasting. These people suffer from a condition ... Northeast Houston Vein Center is offering tips on how to ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Data Integrity ... Within Your Operations or Your Partners/Suppliers, **FDAnews Webinar**, May ... http://www.fdanews.com/DataIntegrity , Data integrity issues have become ... few years., Uncovering data integrity issues within manufacturing operations ... integrity issues come to light, remediating them can be ...
(Date:4/27/2015)... Columbus, OH (PRWEB) April 27, 2015 ... insurance to help his clients feel secure, but also helps ... a.m. to 7 p.m., Douglas will be manning a booth ... Expo Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... this worthy event that will feature hundreds of adoptable pets ...
(Date:4/27/2015)... A' Design Award and Competition is pleased ... by Boombang Inc Design Team has been announced as ... Scientific Instruments, Medical Devices and Research Equipment Design ... Boombang Inc Design Team, the creative team behind the ... Image Lumica is a two-way communication device between patients ...
Breaking Medicine News(10 mins):Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Boombang Inc Design Team wins Platinum in A' Medical Product Design Awards 2
... one of the largest studies in hormone receptor positive ... , PHILADELPHIA, Dec. 11 New ... (lapatinib) plus Femara(R) (letrozole) versus letrozole alone as ... metastatic breast cancer. In the study, women diagnosed with ...
... BOSTON, Dec. 11 The American Federation for,Medical Research ... Tom Daschle,s appointment to the post of Health and ... top,administration official to overhaul the nation,s health care system. ... result of its work since 1940, the AFMR believes ...
... by Matthew L. Myers, President, Campaign for Tobacco-Free Kids: , ... , , It is good ... Future survey released today finds that smoking rates among 8th, ... recorded in this survey for all three grades. However, ...
... released the following statement today on President-elect Obama,s nomination of ... and Human Services and naming him the Director of a ... , "Tom Daschle,s nomination as Secretary of ... the new White House Office of Health Reform is great ...
... among teens is slowing, survey finds , , THURSDAY, Dec. 11 ... among teens, the abuse of painkillers such as Vicodin and ... decline in the use of drugs such as marijuana has ... National Institute on Drug Abuse says in its report, ...
... Midwest Flooding, Indiana Tornadoes , , ... top five disasters of 2008, based on the number of people ... Gustav, Hurricane Ike, the flooding in the Midwest, and the tornadoes ... Weather played a disastrous part in many people,s lives in ...
Cached Medicine News:Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 2Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 3Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 4Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4Health News:10% of U.S. High School Seniors Use Vicodin 2Health News:10% of U.S. High School Seniors Use Vicodin 3Health News:Red Cross Announces Top Five Disaster Responses of 2008 2
Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
Agility has delivered a RFID-enabled mobile asset management program....
Agility can provide tracking and management of surgical instruments, instrument trays and case carts to significantly enhance the current central sterile department flow by improving efficiency....
Assetrac allows identification, location, and protection of your assets....
Medicine Products: